Clinical Trial Update: Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

The Phase 2 pediatric trial evaluating inhaled iloprost for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: WITHDRAWN